SCHEMBL8747018

SCHEMBL8747018

O=C(Cl)C1(c2cccc3ccccc23)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 8/20 0.42
SLC6A4 P31645 7/20 0.42
SLC6A2 P23975 6/20 0.42
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40
NR4A3 Q92570 1/20 0.40
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPK1 P28482 1/20 0.38
MMP3 P08254 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KIF11 P52732 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2A6 P11509 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30344677 1.00 SLC6A3 (0.42) SLC6A3SLC6A4SLC6A2NR4A1NR4A2
SCHEMBL8106448 0.95 SLC6A3 (0.45) SLC6A3SLC6A4SLC6A2NR4A1NR4A2
SCHEMBL697151 0.84 AKR1C1 (0.48) SLC6A3SLC6A4SLC6A2NR4A1NR4A2
SCHEMBL8112531 0.79 AKR1C1 (0.52) SLC6A3SLC6A4SLC6A2NR4A1NR4A2
SCHEMBL12020292 0.77 SLC6A3 (0.46) SLC6A3SLC6A4SLC6A2NR4A1NR4A2
SCHEMBL23972286 0.76 SLC6A3 (0.47) SLC6A3SLC6A4SLC6A2MEN1MAPT
SCHEMBL30604359 0.76 SLC6A3 (0.47) SLC6A3SLC6A4SLC6A2MEN1MAPT
SCHEMBL27926942 0.76 SLC6A3 (0.53) SLC6A3SLC6A4SLC6A2MEN1MAPT
SCHEMBL8747357 0.76 HDAC4 (0.59) SLC6A4
SCHEMBL20241935 0.74 HDAC4 (0.57) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 US disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 WO disclosed
EP-0618900-B1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS KNOLL AG (DE) 1997-03-12 EP disclosed
US-5519034-A ANALGESICS THE BOOTS COMPANY PLC (GB) 1996-05-21 US disclosed
EP-0618900-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. BOOTS CO PLC (GB) 1994-10-12 EP disclosed
WO-1993013073-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS THE BOOTS COMPANY PLC (GB) 1993-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD SLC6A3 4304/4885SLC6A4 3618/4885SLC6A2 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.